Influencia del consumo de fitato sobre la masa ósea en mujeres posmenopáusicas de Mallorca

NIH Consensus Development Panel. Osteoporosis Prevention, Diagnosis, and Therapy. JAMA. 2000;285:785–95. Eisman, 1999, Genetics of osteoporosis, Endocr Rev, 20, 788, 10.1210/er.20.6.788 Paulino, 2000, Osteoporosis: importancia, epidemiología y manifestaciones clínicas, Medicine, 8, 15 Díaz-Curiel, 2001, Prevalencia de osteoporosis determinada por densitometría en la población femenina española, Med Clin (Barc), 116, 86, 10.1016/S0025-7753(01)71732-0 Melton, 1995, How many women have osteoporosis now?, J Bone Miner Res, 10, 175, 10.1002/jbmr.5650100202 Persi, 2000, Densitometría ósea 2000, Med Clin (Barc), 114, 540, 10.1016/S0025-7753(00)71356-X Mellanby, 1949, Rickets-producing and anticalcifying action of phytate, J Physiol, 109, 488, 10.1113/jphysiol.1949.sp004411 Grases, 2004, Effect of Phytate on element bioavailability in the second generation rats, J Trace Elem Med Biol, 17, 229, 10.1016/S0946-672X(04)80023-3 Grases, 1996, Determination of phytic acid in urine by ICP atomic emission spectrometry, Analytical Letters, 29, 1193, 10.1080/00032719608001468 Grases, 2001, Dietary phytate and mineral bioavailability, J Trace Elem Med Biol, 15, 221, 10.1016/S0946-672X(01)80037-7 Grases, 2001, Absorption and excretion of orally administered inositol hexaphosphate IP6 or phytate in humans, BioFactors, 15, 53, 10.1002/biof.5520150105 Grases, 1999, Phytate is a powerful agent for preventing calcifications in biologicals fluids: usefulness in renal lithiasis treatment, Anticancer Res, 19, 3717 Grases, 2000, Kinetic versus thermodynamic factors in calcium renal lithiasis, Int Urol Nephrol, 32, 19, 10.1023/A:1007105328211 Grases, 2000, Inositol hexakisphosphate in urine: the relationship between oral intake and urinary excretion, BJU Int, 85, 138, 10.1046/j.1464-410x.2000.00324.x Grases, 2000, Urinary phytate in calcium oxalate stone formers and healthy people. Dietary effects on phytate excretion, Scand J Urol Nephrol, 34, 162, 10.1080/003655900750016526 Grases, 2006, Phytate (Myo-inositol hexakisphosphate) inhibits cardiovascular calcifications in rats, Frontiers in Bioscience, 11, 136, 10.2741/1786 López-González AA. Influencia de diferentes factores de riesgo incluyendo el myo-inositol hexafosfato cálcico-magnésico en los niveles de densidad mineral ósea en trabajadores de Mallorca. Tesis Doctoral; 2007. Grases F, Sanchis P, Costa-Bauzá A, Perelló J. Phytate (Myo-inositol hexakisphosphate) inhibits hydroxyapatite dissolution [En preparación]. López-González AA, Grases F, Roca P, Marí B, Vicente-Herrero MT, Costa-Bauzá A. Phytate (Myo-inositol hexaphosphate) and risk factors for osteoporosis [en prensa]. J Med Food. 2008;11:747–52. Grases F, Sanchis P, Perelló J, Prieto RM, López-González AA. Effect of phytate (Myo-inositol hexaphosphate) on bone characteristics in ovariectomized rats. J Med Food. 2010 [en prensa]. Fleisch, 2002, Development of bisphosphonates, Breast Cancer Res, 4, 30, 10.1186/bcr414 Fleisch, 2003, Bisphosphonates in osteoporosis, Eur Spine J, 12, 142, 10.1007/s00586-003-0622-z